Developing Site-Specifically Modified ADCs Using A Chemoenzymatic Approach

Summary: Antibody-drug conjugates (ADCs) have become de rigueur for pharmaceutical oncology drug development pipelines. There are more than 40 ADCs undergoing clinical trials and many more in preclinical development. This webinar hosted by Elsevier's Drug Discovery Today presented novel protein modification platform and its application to generate ADCs, including new conjugation chemistries and linkers. 

Click here to download the webinar.